Sachin Shah of Emkay Investment Managers told CNBC-TV18, "Sun Pharmaceutical Industries is getting into an interesting territory now. From a long-term investing perspective, we would wait for the results and maybe next 2-3 months or so, how things pan out. But, I think maybe another 5-10 percent correction, That is about it and clearly, it will come into the buying zone. So, maybe in the range on Rs 750-800, in that band, somewhere around that, I think we should be in decent valuations. And even if you look at the guidance, the way the management was trying to portray things, clearly it is just a short-term blip that we are trying to see in the next 6-9 months. But beyond that, the management is still very confident in terms of the synergy benefit that they are going to get from Ranbaxy.""I think the overall, their strategy in the US market, the way they are expecting it to play out in the next 2-3 years, it think we should see solid earnings growth on a 3-5 year basis. So, this is clearly a great business with a temporary blip and if you get a decent valuation with some more correction, there clearly could be a good opportunity there," he added.Disclosure: Analyst own Bajaj Corp and Infosys.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
